Aurinia Pharmaceuticals Inc. (AUPH) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Edmonton, BC, 加拿大. 现任CEO为 Kevin C. Tang.
AUPH 拥有 IPO日期为 2014-09-03, 130 名全职员工, 在 NASDAQ Global Market, 市值为 $2.14B.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
